vTv Therapeutics Inc.

VTVT · NasdaqCM

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

–

Growth

Health

Risk

–

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders38.8%

Institutions40.7%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$0	$1.02M	$0	$2.02M	$4.00M	$6.41M	$2.76M	$12.43M	$291000	$634000
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$32.81M	-$24.18M	-$25.50M	-$22.54M	-$21.66M	-$11.85M	-$20.89M	-$19.82M	-$50.68M	-$55.02M
Operating income as a percentage of revenue.	–	-2377.6%	–	-1116.9%	-540.9%	-184.8%	-755.9%	-159.4%	-17416.5%	-8678.2%
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$4.11M	-$4.24M	-$5.72M	-$5.91M	-$4.74M	-$4.30M	-$8.89M	-$15.93M	-$38.50M	-$39.00M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-3.20	$-3.20	$-9.71	$-0.26	$-0.21	–	$0.00	$0.00	$-1.00	$-1.00
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-3.20	$-3.20	$-9.71	$-0.26	–	–	–	–	–	–

Balance Sheet

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$88.90M	$36.70M	$9.40M	$12.10M	$13.40M	$5.75M	$1.78M	$1.68M	$11.76M	$51.51M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$89.90M	$38.27M	$11.02M	$33.24M	$25.47M	$14.79M	$9.27M	$8.56M	$27.92M	$54.49M
All of the company's interest-bearing borrowings, short and long term combined.	–	$0	$191000	$224000	$256000	$84000	$6.17M	$9.38M	$4.27M	–
Everything the company owes — debt, unpaid bills, and other obligations.	$25.46M	$23.96M	$29.57M	$27.40M	$10.25M	$11.00M	$18.11M	$28.93M	$47.52M	$22.93M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$64.44M	$12.20M	-$24.68M	-$10.74M	-$9.74M	-$80.10M	-$49.02M	-$82.85M	-$151.05M	-$90.94M

Cash Flow Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$25.25M	-$25.31M	-$19.08M	-$16.02M	-$19.31M	-$18.00M	-$23.02M	-$26.86M	-$44.56M	-$48.21M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	–	$0	$0	$21000	–	–	$70000	$5000	$57000	$87000
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	–	-$25.31M	-$19.08M	-$16.04M	–	–	-$23.09M	-$26.86M	-$44.62M	-$48.30M

	You	Peer avg
Revenue Growth	–	-53.9%
ROE	-15.8%	-110.2%

vTv Therapeutics Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison